Therapeutic circular RNAs (circRNAs) are progressing from preclinical development to clinical evaluation, and esophageal squamous cell carcinoma (ESCC) may become a future indication for circRNA-based immunotherapy, potentially including first-line use…
Platelet response and clinical remission remain central measures of clinical control in immune thrombocytopenia (ITP), but they do not establish whether disease-relevant immune activity has durably receded. We propose immune remission as a provisional,…
BackgroundChimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) have transformed treatment for relapsed/refractory multiple myeloma (RRMM). Contemporary guidelines increasingly incorporate prior antigen-directed exposure, d…
Systemic sclerosis (SSc) is a complex autoimmune disease marked by vasculopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. The high disease burden and impact on quality of life highlight the need for therapies that…
Studies of microbiome-targeted interventions often use persistence of an administered organism or endpoint metabolite abundance as markers of biological consequence, but host barriers may be altered by microbial chemistry after the initiating exposure …
CAR T-cell therapy has demonstrated the capacity to induce deep, drug-free remissions in patients with severe, refractory systemic lupus erythematosus (SLE), including those with lupus nephritis (LN). These observations challenge long-standing assumpti…
Relapse remains the most significant cause of mortality after allogeneic transplant for leukemia despite advances in understanding of disease biology and newer, targeted treatment modalities. Cure after allogeneic transplant is mediated through the gra…
Resistance to cancer immunotherapy is frequently sustained by immune exclusion, suppressive myeloid and stromal programs, abnormal tumor vasculature, and inhibitory checkpoint-ligand expression within the tumor microenvironment. Activation of the cGAS-…
X-ray repair cross-complementing protein 1 (XRCC1) is a scaffold protein that functions as a molecular hub, serving as a platform for the recruitment and interaction of multiple DNA repair proteins to coordinate and facilitate multistep DNA repair proc…
Chimeric antigen receptor (CAR) T cells are capable to eliminate cancer cells in the treatment of hematologic malignancies, yet the efficacy is frequently inconsistent and limited by cancer cell resistance and antigen-loss resulting in early tumor rela…
